♟️ Friday 25 July 2025 Fri, 25 July 2025

Lanthanein Resources has completed diamond drilling at its Lady Grey Project, reported promising assay results, and launched a $2.4 million capital raising alongside a proposed rebrand to Fortuna Metals.

Tivan Limited has identified three new copper mineralisation sites at its Turiscai Project in Timor-Leste, advancing its early-stage exploration with assay results expected in September 2025.

Cuscal Limited announces the retirement of long-serving CFO Sean O’Donoghue in late 2025 and the appointment of Jennifer Brice as his successor, signaling a seamless leadership transition as the company remains on track to meet its FY25 forecasts.

Renascor Resources has successfully produced high-grade graphite concentrate from its Siviour deposit, exceeding feasibility study benchmarks and setting the stage for its Australian Government-backed PSG demonstration plant. This milestone comes as US tariffs on Chinese anode materials surge, spotlighting Renascor’s strategic role in diversifying supply.

Singular Health has landed a pivotal $2 million US pilot contract with Provider Network Solutions and completed an $8 million capital raise, advancing its medical imaging platform’s regulatory and product development milestones.

Newmont Corporation reported a robust second quarter in 2025, driven by higher gold prices, successful divestitures of non-core assets, and strong operational performance, reinforcing its financial strength and strategic focus.

Newmont Corporation reported a robust second quarter in 2025, highlighted by record free cash flow and a fresh $3 billion share repurchase program, while reaffirming its full-year guidance.

The Commerce Commission has issued a Statement of Issues regarding Viridian NZ Bidco’s proposed acquisition of Metro Glass, highlighting potential competition risks in New Zealand’s glass processing and installation markets.

Peak Rare Earths Limited has updated its acquisition scheme, replacing Ganzhou Chenguang with Shenghe Resources (Singapore) Pte. Ltd. as the acquiring party, simplifying regulatory hurdles and valuing the company at nearly A$158 million.

Echo IQ has secured a strategic collaboration with the Mayo Clinic Platform and raised $17.3 million, advancing its AI-driven cardiology tools towards FDA clearance and US commercial scale.